The population density of Hodgenville, KY was 1,566 in 2014. The population density of Providence, KY was 521 in 2014.
Population Density
Population Density is computed by dividing the total population by Land Area Per Square Mile.
Above charts are based on data from the U.S. Census American Community Survey | ODN Dataset | API -
Geographic and Population Datasets Involving Providence, KY or Hodgenville, KY
- API
Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status
data.cdc.gov | Last Updated 2023-07-20T16:01:58.000ZData for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases
- API
FY 2021_NCVAS Vet Pop Change Data For State Summaries
www.datahub.va.gov | Last Updated 2024-08-26T02:19:14.000ZThese data are based on the latest Veteran Population Projection Model, VetPop2020, provided by the National Center for Veterans Statistics and Analysis, published in 2023.
- API
Creating Healthy Communities Coalition (CHCC) Activities
data.cincinnati-oh.gov | Last Updated 2021-08-16T14:41:08.000ZData Description: This dataset contains information on the Cincinnati Health Department's (CHD) Creating Healthy Communities Coalition (CHCC). Creating Health Communities is an Ohio Department of Health (ODH) program. This dataset has the location and estimated number of people impacted by CHCC activities implemented in 2015-2017. For more information, visit https://www.cincinnati-oh.gov/health/cincinnati-health-department-divisions1/environmental-health/health-promotion-worksite-wellness/ Disclaimers: The CHCC dashboard includes data from outside the city limits, including Northern Kentucky, Hamilton County, Columbus area, and Dayton area, for the following measures: UDF Healthy Food Retail, Produce Perks, and Tobacco Free Policies. A residential population may be impacted by multiple PSE changes, due to the location of various PSE changes. For example, in 2015 the Stanley Rowe Senior Citizens population was impacted by a Crime Prevention Through Environmental Design PSE change. The same population was impacted again in 2016 with a Smoke-free Policy change. Data Creation: The Cincinnati Health Department provides updates on each CHCC activity impacting Cincinnati residents Data Created By: Cincinnati Health Department Refresh Frequency: Daily CincyInsights: The City of Cincinnati maintains an interactive dashboard portal, CincyInsights in addition to our Open Data in an effort to increase access and usage of city data. This data set has an associated dashboard available here: https://insights.cincinnati-oh.gov/stories/s/5ygy-4y6j Data Dictionary: A data dictionary providing definitions of columns and attributes is available as an attachment to this dataset. Processing: The City of Cincinnati is committed to providing the most granular and accurate data possible. In that pursuit the Office of Performance and Data Analytics facilitates standard processing to most raw data prior to publication. Processing includes but is not limited: address verification, geocoding, decoding attributes, and addition of administrative areas (i.e. Census, neighborhoods, police districts, etc.). Data Usage: For directions on downloading and using open data please visit our How-to Guide: https://data.cincinnati-oh.gov/dataset/Open-Data-How-To-Guide/gdr9-g3ad
- API
Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status and Booster Dose
data.cdc.gov | Last Updated 2023-06-09T00:47:32.000ZData for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases
- API
Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status and Second Booster Dose
data.cdc.gov | Last Updated 2023-06-09T00:48:07.000ZData for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases
- API
COVID-19 Case Surveillance Public Use Data
data.cdc.gov | Last Updated 2024-07-17T19:39:47.000Z<b>Note:</b> Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated. Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death. This case surveillance public use dataset has 12 elements for all COVID-19 cases shared with CDC and includes demographics, any exposure history, disease severity indicators and outcomes, presence of any underlying medical conditions and risk behaviors, and no geographic data. <h4><b>CDC has three COVID-19 case surveillance datasets:</b></h4><ul><li><a href="https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveillance-Public-Use-Data-with-Ge/n8mc-b4w4">COVID-19 Case Surveillance Public Use Data with Geography</a>: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements)</li><li><a href="https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveillance-Public-Use-Data/vbim-akqf">COVID-19 Case Surveillance Public Use Data</a>: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements)</li><li><a href="https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveillance-Restricted-Access-Detai/mbd7-r32t">COVID-19 Case Surveillance Restricted Access Detailed Data</a>: Restricted access, patient-level dataset with clinical and symptom data, demographics, and state and county of residence. Access requires a registration process and a data use agreement. (33 data elements)</li></ul> The following apply to all three datasets: <ul><li>Data elements can be found on the COVID-19 case report form located at <a href="https://www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf">www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf</a>.</li><li>Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.</li><li>Some data cells are suppressed to protect individual privacy.</li><li>The datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensures that time-dependent outcome data are accurately captured.</li><li>Datasets are updated monthly.</li><li>Datasets are created using CDC’s <a href="https://www.cdc.gov/grants/additional-requirements/ar-25.html">Policy on Public Health Research and Nonresearch Data Management and Access</a> and include protections designed to protect individual privacy.</li><li>For more information about data collection and reporting, please see <a href="https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html">https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.</a></li><li>For more information about the COVID-19 case surveillance data, please see <a href="https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html"> https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html</a><br></li></ul> <h4><b>Overview</b></h4> The COVID-19 case surveillance database includes individual-level data reported to U.S. states and aut